Pediatric Brain Tumors

Chimeric antigen receptor T-cell therapy can reduce tumor burden and improve neurologic function for patients with certain brain and spinal cord cancers, a first-in-human clinical trial showed.

PHILADELPHIA — In this video, Michael Fisher, MD, highlights a keynote presentation given by Charles Limoli, PhD, at the International Symposium on Pediatric Neuro-Oncology.

PHILADELPHIA — In this video, Michael Fisher, MD, highlights the sessions and presentations at the International Symposium on Pediatric Neuro-Oncology.

An mRNA cancer vaccine developed at University of Florida may have the ability to reprogram the immune system against glioblastoma, findings of a first-in-human trial showed.

Glioblastoma, the most common primary brain cancer, is known to be highly aggressive and deadly.

The oncolytic adenovirus DNX-2401 appeared safe and feasible among a small cohort of pediatric patients with diffuse intrinsic pontine glioma, according to study results published in The New England Journal of Medicine.

The FDA granted orphan drug designation to silmitasertib for treatment of medulloblastoma.

In a recent study, researchers found that antihypertensive drugs could potentially reduce mortality among patients with stage I to stage III colorectal cancer. It was the top story in hematology/oncology last week.

Nearly 20% of pediatric brain tumors occur in the pituitary region, and more than two-thirds of pituitary region tumors were present in girls, according to study findings published in Pituitary.